A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

The Lancet Infectious Diseases - Tập 13 - Trang 269-275 - 2013
John H Rex1,2, Barry I Eisenstein3,4, Jeff Alder5, Mark Goldberger6, Robert Meyer7, Aaron Dane8, Ian Friedland4, Charles Knirsch9, Wendy R Sanhai10, John Tomayko11, Cindy Lancaster12, Jennifer Jackson4
1University of Texas Medical School at Houston, Houston, TX, USA.
2AstraZeneca Pharmaceuticals, Waltham, MA, USA
3Harvard Medical School, Boston, MA, USA
4Cubist Pharmaceuticals, Lexington, MA, USA
5Bayer HealthCare Pharmaceuticals, Montville, NJ, USA
6AbbVie, Rockville, MD, USA
7Merck and Co, North Wales, PA, USA
8AstraZeneca Pharmaceuticals, Macclesfield, UK
9Pfizer Pharmaceuticals, Groton, CT, USA
10GlaxoSmithKline, Research Triangle Park, NC, USA
11GlaxoSmithKline, Upper Providence, PA, USA
12AstraZeneca Pharmaceuticals, Wilmington, DE, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Infectious Diseases

Tập 13

269-275

Thông tin tác giả